Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Quest Diagnostics Selling Ovarian Cancer Test

By Drug Discovery Trends Editor | March 9, 2010

NEW YORK (AP) – Medical lab operator Quest Diagnostics Inc. said it is selling the OVA1 blood test, which aims to better assess a woman’s likelihood for ovarian cancer.

The OVA1 test, which was approved by the Food and Drug Administration in September, will be sold through Quest, based in Madison, N.J. The test was developed in collaboration with molecular diagnostics company Vermillion Inc.

OVA1 is used as a pre-surgical evaluation of a woman’s ovarian mass for cancer. It allows physicians to assess, before a planned surgery, the likelihood that a woman’s ovarian mass is malignant. The test allows physicians to direct the patient to a specialist more quickly, the company said.

“The availability of a new test that can help gynecologists and other physicians determine the likelihood a woman’s mass is benign or malignant is a significant development in the battle against this devastating disease,” said Dr. Karen Orloff Kaplan, CEO of the patient advocacy group the Ovarian Cancer National Alliance, in a statement. “It is a big step towards helping each woman get the most appropriate care for her unique situation.”

Ovarian cancer is the leading cause of death from gynecologic cancers in the U.S. and the fifth-leading cause of cancer deaths in women, Quest said. Ovarian masses affect an estimated 1 million women and lead to as many 300,000 ovarian mass surgeries in the U.S. each year, Quest added, citing an analysis by third parties on behalf of the company.

The company said about 21,600 new cases of ovarian cancer will be diagnosed in the U.S. in 2009, and about 14,600 women will die of the disease.

Date: March 8, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50